

Supplementary table 1. Number of patients contributed by each registry

	Total n (%)	JAKi to JAKi n (%)	JAKi to bDMARD n (%)	Date of first entry	Date of last entry
Total	2000 (100)	365 (18.3)	1635 (81.7%)	15-08-2013	08-09-2021
Austria, BIOREG	74 (3.7)	8 (2.2)	66 (4.0)	15-06-2016	13-04-2021
Canada, RHUMADATA	79 (3.95)	9 (2.5)	70 (4.3)	09-09-2014	15-02-2021
Czech Republic, ATTRA	192 (9.6)	40 (11.0)	152 (9.3)	30-08-2017	13-05-2021
Finland, ROB-FIN	154 (7.7)	27 (7.4)	127 (7.8)	18-06-2017	18-09-2020
Germany, RABBIT	77 (3.85)	18 (4.9)	59 (3.6)	21-07-2017	23-12-2019
Italy, GISEA	207 (10.35)	46 (12.6)	161 (9.8)	14-12-2017	08-09-2021
Israel, I-RECORD	17 (0.85)	0 (0.0)	17 (1.0)	15-09-2014	17-03-2019
Netherlands, METEOR	1 (0.05)	0 (0.0)	1 (0.1)	25-10-2017	25-10-2017
Norway, NOR-DMARD	25 (1.25)	2 (0.5)	23 (1.4)	09-10-2017	24-01-2019
Portugal, REUMA.PT	26 (1.3)	2 (0.5)	24 (1.5)	23-07-2018	24-05-2021
Romania, RRBR	124 (6.2)	3 (0.8)	121 (7.4)	26-03-2018	13-04-2021
Russia, ARBITR	8 (0.4)	0 (0.0)	8 (0.5)	22-08-2014	15-02-2019
Slovenia, BIORX.SI	66 (3.3)	15 (4.1)	51 (3.1)	19-09-2017	29-03-2021
Spain, BIOBADASER	276 (13.8)	79 (21.6)	197 (12.0)	02-10-2017	10-05-2021
Switzerland, SCQM	419 (20.95)	90 (24.7)	329 (20.1)	15-08-2013	19-05-2021
Turkey, TURKBIO	138 (6.9)	0 (0.0)	138 (8.4)	15-07-2015	24-09-2020
UK, BSRBR	117 (5.85)	26 (7.1)	91 (5.6)	20-01-2017	18-08-2020

bDMARD, biologic disease-modifying antirheumatic drug; JAKi, Janus kinase inhibitor.